Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Goodenough

Plastic Surgery New Orleans, LA Medical Doctor

NPI 1477997815 CMS profile 4580556

4414 Carondelet St, New Orleans, LA 70115

Open in the dashboard

General payments

$8,004

82 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Goodenough of New Orleans, LA is reported in the CMS Open Payments database as having received $8,004 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $119 1
2024 General $761 9
2023 General $539 5
2022 General $705 7
2021 General $3,147 31
2020 General $929 10
2019 General $1,804 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Goodenough
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Christopher Goodenough were reported at $119. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Christopher Goodenough Plastic Surgery median Middle half National median
2019 $1,804 $371 $122–$1,483 $163
2020 $929 $158 $52–$438 $114
2021 $3,147 $249 $87–$752 $132
2022 $705 $274 $102–$793 $149
2023 $539 $299 $113–$891 $160
2024 $761 $361 $124–$1,062 $164
2025 $119 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $3,128 27 payments
  2. AxoGen $2,633 27 payments
  3. Integra LifeSciences Corporation $313 4 payments
  4. Checkpoint Surgical, Inc $293 3 payments
  5. AbbVie, Inc. $261 2 payments
  6. Mentor Worldwide LLC $259 3 payments
  7. Stryker Corporation $162 1 payment
  8. Sonex Health, Inc. $126 1 payment
  9. Davol Inc. $125 1 payment
  10. Acell, Inc. $125 1 payment
  11. Other $578 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,608 78 payments
  2. Travel and Lodging $343 3 payments
  3. Long term medical supply or device loan $53 1 payment
Products named General payments · program years 2019–2025
  1. Avance Nerve Graft $1,643 18 payments
  2. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $1,567 13 payments
  3. NATRELLE $1,381 11 payments
  4. AxoGuard Nerve Connector $1,015 10 payments
  5. AXOGUARD NERVE PROTECTOR $1,015 10 payments
  6. Checkpoint Stimulators $293 3 payments
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $261 2 payments
  8. Integra Recon-Skin And Wound $260 3 payments
  9. Integra Recon-Skin And Wound $260 3 payments
  10. INTEGRA DERMAL REGENERATION TEMPLATE $260 3 payments
  11. Other $2,334 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$61,382

Medicare's payments for the services billed

Medicare patients

56

Average age 68

Services billed

309

28 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 57%
Depression 32%
Diabetes 25%
Atrial fibrillation 23%
Ischemic heart disease 20%
Chronic kidney disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record